Novavax seeks FDA approval for updated Covid-19 vaccine
Pharmaceutical Technology
JUNE 17, 2024
Novavax has sought US FDA approval for an updated JN.1 version of its Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above.
Mon.Jun 17, 2024
363 
New data showcase promise, growing pains of CAR-T in autoimmune disease
Bio Pharma Dive
JUNE 17, 2024
One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia).
The critical role of comprehensive RNA sequencing in liquid biopsy for biomarker discovery and clinical trials
Bio Pharma Dive
JUNE 17, 2024
Elevate precision medicine: dose optimization and immune monitoring through advanced liquid biopsies.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments
Bio Pharma Dive
JUNE 17, 2024
The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Report recommends ways to improve availability and affordability of essential medical devices
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 17, 2024
Incentivising domestic production of essential medical devices, building a robust logistics infrastructure and supplier network with stringent quality control measures and certification standards, and proper pricing policies are some of the ways to grow the medical devices sector in the country and to improve availability and affordability across the country, according to a recent report.
MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine.
June 17, 2024: This Week’s PCT Grand Rounds to Feature Trial of Electronic Cigarettes for Smoking Cessation
Rethinking Clinical Trials
JUNE 17, 2024
Dr. Reto Auer In this Friday’s PCT Grand Rounds, Reto Auer of the University of Bern will present “Efficacy and Safety of Electronic Cigarettes for Smoking Cessation: Keeping a Trial on a Polarizing Topic Running Under Regulatory and Epidemic Changes.” The Grand Rounds session will be held on Friday, June 21, 2024, at 1:00 pm eastern.
OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Visceral Pain.
Takeda drug for rare types of epilepsy misses goal in late-stage trial
Bio Pharma Dive
JUNE 17, 2024
Called soticlestat, the drug had seemed promising in earlier studies for people with Dravet and Lennox-Gastaut syndrome, enough to persuade Takeda to take on full rights to the drug.
Olanzapine by Neurelis for Bipolar Disorder (Manic Depression): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Olanzapine is under clinical development by Neurelis and currently in Phase I for Bipolar Disorder (Manic Depression).
Early patient engagement can improve medication adherence. Here’s how.
Bio Pharma Dive
JUNE 17, 2024
Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients as soon as a medicine is prescribed can help.
Ferric carboxymaltose by Vifor Pharma Management for Restless Legs Syndrome: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in Phase III for Restless Legs Syndrome.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Leuko device to remotely monitor cancer patients during chemotherapy
Pharma Times
JUNE 17, 2024
Cancer was estimated to be responsible for more than 18 million cases worldwide in 2020
Daxdilimab by Amgen for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Daxdilimab is under clinical development by Amgen and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM).
Merck gets shot in the arm with FDA approval for first pneumococcal vaccine designed for adults
Fierce Pharma
JUNE 17, 2024
The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by senio | The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by seniors to protect against the bacterial infection.
Dabrafenib mesylate by Novartis for Follicular Thyroid Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Follicular Thyroid Cancer.
From market withdrawal back to £3B peak sales: GSK dreams big for myeloma ADC Blenrep
Fierce Pharma
JUNE 17, 2024
Two back-to-back pivotal trial wins have rekindled hopes at GSK that once-failed multiple myeloma drug Blenrep could reach more than 3 billion pounds sterling in peak sales after all. | Two back-to-back pivotal trial wins have rekindled hopes at GSK that once-failed multiple myeloma drug Blenrep could reach more than 3 billion pounds sterling in peak sales after all.
Apalutamide by Johnson & Johnson for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Apalutamide is under clinical development by Johnson & Johnson and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Ten-minute brain scan could improve diagnosis for paediatric brain cancer
Pharma Times
JUNE 17, 2024
Medulloblastoma is responsible for around 52 new cases in children in the UK every year
Daxdilimab by Amgen for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Daxdilimab is under clinical development by Amgen and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Could Amazon or Google hold the key to the future of public health diagnostics?
pharmaphorum
JUNE 17, 2024
Discover how leading tech giants such as Amazon, Google, Apple, and Microsoft are shaping the future of public health diagnostics through MedTech innovations. Explore the potential impact on healthcare and stay informed on the latest developments.
Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Olanzapine ER is under clinical development by Teva Pharmaceutical Industries and currently in Phase III for Schizophrenia.
Upscaling your brand strategy: New ways of planning
pharmaphorum
JUNE 17, 2024
Learn how to upscale your brand strategy with new and innovative ways of planning. Discover effective brand planning strategies to take your brand to the next level.
EHA 2024: AstraZeneca’s Calquence plus chemoimmunotherapy offers new standard for MCL
Pharmaceutical Technology
JUNE 17, 2024
If Calquence receives FDA label expansion in MCL, it will achieve a unique position in the treatment-naive MCL market share.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
New data at EHA backs Sanofi, Innate’s NK cell engager
pharmaphorum
JUNE 17, 2024
Sanofi and Innate Pharma NK cell engager therapy SAR443579 shows promising efficacy in AML patients in a phase 1/2 trial reported at EHA.
Feladilimab by GSK for Metastatic Melanoma: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Feladilimab is under clinical development by GSK and currently in Phase II for Metastatic Melanoma.
Address the impact of trending health information with conversation data
pharmaphorum
JUNE 17, 2024
Explore the impact and influence of trending health information, like Ozempic and the Eddy Effect on platforms like TikTok, through conversation data analysis. Learn more about these trends and their implications.
Feladilimab by GSK for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
JUNE 17, 2024
Feladilimab is under clinical development by GSK and currently in Phase II for Solid Tumor.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content